Alan Olby joined the Board as Chief Financial Officer in June 2023. Alan is a chartered accountant with over 20 years’ experience in finance leadership roles in life science companies. Alan previously spent 16 years at Sinclair Pharma, 12 as Chief Financial Officer, playing a key role in transforming the business into a fast growth global aesthetics business, initially as an AIM listed group and subsequently under private ownership following the sale to Huadong Medicine Co Ltd (China) in 2018. Alan has overseen a number of strategically important M&A transactions and capital raisings, while also managing the operational financial challenges of a growing international business.

Key Areas of expertise:

Financial planning & management, working capital management, business partnering, financing, M&A, risk management, investor relations